Pre-made Anifrolumab benchmark antibody ( Whole mAb, anti-IFNAR1 therapeutic antibody, Anti-AVP/IFN-alpha-REC/IFNAR/IFNBR/IFRC Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Anifrolumab biosimilar, Whole mAb, Anti-IFNAR1 Antibody: Anti-AVP/IFN-alpha-REC/IFNAR/IFNBR/IFRC therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Anifrolumab[1] is a monoclonal antibody designed for the treatment of systemic lupus erythematosus (SLE). It binds to the type I interferon receptor, blocking the activity of type I interferons such as interferon-¦Á and interferon-¦Â.
| Products Name (INN Index) | Pre-Made Anifrolumab biosimilar, Whole mAb, Anti-IFNAR1 Antibody: Anti-AVP/IFN-alpha-REC/IFNAR/IFNBR/IFRC therapeutic antibody |
|---|---|
| INN Name | Anifrolumab |
| Target | IFNAR1 |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Approved |
| Est. Status | Active |
| 100% SI Structure | 4qxg:HL |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2013 |
| Year Recommended | 2014 |
| Companies | Medarex,Medical University of Vienna,MedImmune |
| Conditions Approved | Systemic lupus erythematosus |
| Conditions Active | Lupus nephritis |
| Conditions Discontinued | Rheumatoid arthritis,Scleroderma |
| Development Tech | Medarex UltiMAb Mouse |
| Previous Name | NA |
| Gm Offical Target Name | IFNAR1 |
| Package |
